DDInter458 DDInter1925
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Cyclosporine {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Cyclosporine {u} (Compound) downregulates {v} (Gene) BRCA1
BRCA1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Cyclosporine {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
P-Glycoprotein Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Vemurafenib
Cyclosporine {u} (Compound) downregulates {v} (Gene) DNTTIP2
DNTTIP2 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Cyclosporine {u} (Compound) upregulates {v} (Gene) MANF
MANF {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Cyclosporine {u} (Compound) causes {v} (Side Effect) Myalgia
Myalgia {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Cyclosporine {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) regulates {v} (Gene) FAM63A
FAM63A {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Cyclosporine {u} (Compound) binds {v} (Gene) ABCC1
ABCC1 {u} (Gene) is regulated by {v} (Gene) PAN2
PAN2 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Cyclosporine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Cyclosporine (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Vemurafenib (Compound)
Cyclosporine (Compound) downregulates BRCA1 (Gene) and BRCA1 (Gene) is upregulated by Vemurafenib (Compound)
Cyclosporine (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class) and P-Glycoprotein Inhibitors (Pharmacologic Class) includes Vemurafenib (Compound)
Cyclosporine (Compound) downregulates DNTTIP2 (Gene) and DNTTIP2 (Gene) is downregulated by Vemurafenib (Compound)
Cyclosporine (Compound) upregulates MANF (Gene) and MANF (Gene) is downregulated by Vemurafenib (Compound)
Cyclosporine (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Vemurafenib (Compound)
Cyclosporine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Cyclosporine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) regulates FAM63A (Gene) and FAM63A (Gene) is upregulated by Vemurafenib (Compound)
Cyclosporine (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is regulated by PAN2 (Gene) and PAN2 (Gene) is upregulated by Vemurafenib (Compound)